Real-life experience of guselkumab in patients with psoriasis.
guselkumab
psoriasis
real world
Journal
Dermatologic therapy
ISSN: 1529-8019
Titre abrégé: Dermatol Ther
Pays: United States
ID NLM: 9700070
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
received:
19
05
2020
revised:
19
06
2020
accepted:
26
06
2020
pubmed:
4
7
2020
medline:
15
5
2021
entrez:
4
7
2020
Statut:
ppublish
Résumé
High levels of efficacy were demonstrated in randomized controlled trials assessing the efficacy of guselkumab; however, real-life data are lacking. In this retrospective cohort study, we assessed the efficacy and safety of guselkumab in a cohort of psoriasis patients heavily pretreated with biologic agents. Primary efficacy endpoint was the percentage of patients achieving ≥psoriasis area and severity index (PASI) 90 response at week 24. The cohort included 33 patients of mean age 60 ± 13 years. Guselkumab was initiated after a mean of 4.0 ± 1.0 prior biologics failed over a mean period of 7. 4 ± 3.8 years. The mean duration of guselkumab treatment was 9.5 ± 3.7 months; 29 patients completed at least 24 weeks of treatment. At week 24, 22 patients (76%) achieved response of PASI 75 or higher, 18 (62%) achieved PASI 90 or higher, five (17%) PASI 100, and seven (24%) ≤PASI 50. No adverse effects were observed. This study confirms the efficacy and safety of guselkumab in real-world clinical practice, although for a lesser degree compared with clinical trials.
Substances chimiques
Antibodies, Monoclonal
0
Antibodies, Monoclonal, Humanized
0
guselkumab
089658A12D
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13964Informations de copyright
© 2020 Wiley Periodicals LLC.
Références
Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol. 2009;60(4):643-659. https://doi.org/10.1016/j.jaad.2008.12.032.
Lebwohl MG, Kavanaugh A, Armstrong AW, Van Voorhees AS. US perspectives in the management of psoriasis and psoriatic arthritis: patient and physician results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) survey. Am J Clin Dermatol. 2016;17(1):87-97. https://doi.org/10.1007/s40257-015-0169-x.
Blome C, Gosau R, Radtke MA, et al. Patient-relevant treatment goals in psoriasis. Arch Dermatol Res. 2016;308(2):69-78. https://doi.org/10.1007/s00403-015-1613-8.
Gordon KB, Duffin KC, Bissonnette R, et al. A phase 2 trial of guselkumab versus adalimumab for plaque psoriasis. N Engl J Med. 2015;373(2):136-144. https://doi.org/10.1056/NEJMoa1501646.
Reich K, Armstrong AW, Foley P, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol. 2017;76(3):418-431. https://doi.org/10.1016/j.jaad.2016.11.042.
Deza G, Notario J, Lopez-Ferrer A, et al. Initial results of ixekizumab efficacy and safety in real-world plaque psoriasis patients: a multicentre retrospective study. J Eur Acad Dermatol Venereol. 2019;33(3):553-559. https://doi.org/10.1111/jdv.15288.
Sherman S, Solomon Cohen E, Amitay-Laish I, Hodak E, Pavlovsky L. IL-17A inhibitor switching - efficacy of iekizumab following secukinumab failure. A single-center experience. Acta Derm Venereol. 2019;99(9):769-773. https://doi.org/10.2340/00015555-3200.
Fougerousse A-C, Ghislain P-D, Reguiai Z, et al. Effectiveness and short-term (16-week) tolerance of guselkumab for psoriasis under real-life conditions: a retrospective multicenter study. J Eur Acad Dermatol Venereol. 2020 Apr 20 [Epub ahead of print]. https://doi.org/10.1111/jdv.16511.
Puig L. Obesity and psoriasis: body weight and body mass index influence the response to biological treatment. J Eur Acad Dermatol Venereol. 2011;25(9):1007-1011. https://doi.org/10.1111/j.1468-3083.2011.04065.x.
Momose M, Asahina A, Umezawa Y, Nakagawa H. Long-term clinical efficacy and safety of secukinumab for Japanese patients with psoriasis: a single-center experience. J Dermatol. 2018;45(3):318-321. https://doi.org/10.1111/1346-8138.14145.